Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,161 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Rationale and design of a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction: the morBidity-mortality EvAlUaTion of the I(f) inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction (BEAUTIFUL) study.
Fox K, Ferrari R, Tendera M, Steg PG, Ford I; BEAUTIFUL Steering Committee. Fox K, et al. Am Heart J. 2006 Nov;152(5):860-6. doi: 10.1016/j.ahj.2006.01.013. Am Heart J. 2006. PMID: 17070146
Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial.
Fox K, Ford I, Steg PG, Tendera M, Robertson M, Ferrari R; BEAUTIFUL Investigators. Fox K, et al. Eur Heart J. 2009 Oct;30(19):2337-45. doi: 10.1093/eurheartj/ehp358. Epub 2009 Aug 31. Eur Heart J. 2009. PMID: 19720635 Clinical Trial.
Cardiovascular mortality and heart failure risk score for patients after ST-segment elevation acute myocardial infarction treated with primary percutaneous coronary intervention (Data from the Leiden MISSION! Infarct Registry).
Antoni ML, Hoogslag GE, Boden H, Liem SS, Boersma E, Fox K, Schalij MJ, Bax JJ, Delgado V. Antoni ML, et al. Among authors: fox k. Am J Cardiol. 2012 Jan 15;109(2):187-94. doi: 10.1016/j.amjcard.2011.08.029. Am J Cardiol. 2012. PMID: 22244127
Rationale, design, and baseline characteristics of the Study assessInG the morbidity-mortality beNefits of the If inhibitor ivabradine in patients with coronarY artery disease (SIGNIFY trial): a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease without clinical heart failure.
Fox K, Ford I, Steg PG, Tardif JC, Tendera M, Ferrari R. Fox K, et al. Am Heart J. 2013 Oct;166(4):654-661.e6. doi: 10.1016/j.ahj.2013.06.024. Epub 2013 Sep 17. Am Heart J. 2013. PMID: 24093844 Free article. Clinical Trial.
The wealth of nations and the dissemination of cardiovascular research.
Winnik S, Speer T, Raptis DA, Walker JH, Hasun M, Clavien PA, Komajda M, Bax JJ, Tendera M, Fox K, Van de Werf F, Mundow C, Lüscher TF, Ruschitzka F, Nallamothu BK, Matter CM. Winnik S, et al. Among authors: fox k. Int J Cardiol. 2013 Nov 5;169(3):190-5. doi: 10.1016/j.ijcard.2013.08.101. Epub 2013 Sep 10. Int J Cardiol. 2013. PMID: 24139785 Free article. Clinical Trial.
3,161 results